API
< Back to all clusters
[HEALTH] · Italy · 19 sources

started · updated

AIOM reports low awareness of precision oncology in breast cancer patients

A survey conducted by the Fondazione Aiom, involving 752 patients and caregivers, reveals significant gaps in knowledge regarding precision oncology for breast cancer treatment. The findings, presented at the XXVIII National Congress of the Italian Association of Medical Oncology (Aiom), indicate that only 32% of respondents are aware of liquid biopsies, and 43% are unfamiliar with targeted cancer therapies.

Furthermore, only 24% of those surveyed understand the role of Molecular Tumor Boards, while 95% are unfamiliar with Next-generation sequencing (NGS) technology used for genetic analysis. Despite these knowledge gaps, 80% of participants expressed a desire for increased dialogue with medical professionals to select appropriate treatments.

Massimo Di Maio, president of Aiom, emphasized that while access to drugs has historically been a primary concern, timely access to molecular diagnostic tests is now a critical issue. Without efficient access to these tests, patients risk missing out on potentially effective targeted therapies. The survey is part of a broader campaign to increase awareness and improve care pathways through digital tools and educational resources.

Entities

Aiom Foundation · Annamaria Colao · Associazione Italiana di Oncologia Medica · Associazione italiana oncologia medica · Fondazione Aiom · Francesco Perrone · Italian Association of Medical Oncology · Massimo Di Maio · Menarini Stemline · Raffaella Cesaroni · Rome · University of Naples Federico II

Sources